HighMark Wealth Management’s Adaptimmune Therapeutics ADAP Stock Holding History

HighMark Wealth Management’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-287	Closed	-$37	–	588
2025 Q3	$37	Hold	287	–	–	﹤0.01%	601
2025 Q2	$69	Hold	287	–	–	﹤0.01%	607
2025 Q1	$57	Hold	287	–	–	﹤0.01%	564
2024 Q4	$155	Hold	287	–	–	﹤0.01%	554
2024 Q3	$273	Hold	287	–	–	﹤0.01%	562
2024 Q2	$280	Hold	287	–	–	﹤0.01%	555
2024 Q1	$453	Hold	287	–	–	﹤0.01%	529
2023 Q4	$228	Hold	287	–	–	﹤0.01%	552
2023 Q3	$224	Sell	287 -982	-77%	-$824	﹤0.01%	543
2023 Q2	$1.17K	Buy	+1,269	New	+$1.51K	﹤0.01%	492

Other funds holding ADAP

JAIC

Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return

Empirical Finance Havertown, Pennsylvania $2.13B AUM 29.56% 1-Year Est. Return

Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

HighMark Wealth Management's ADAP Position: Q4 2025 in Review

HighMark Wealth Management sold out of Adaptimmune Therapeutics (ADAP) in Q4 2025, closing a stake of 287 shares — an estimated $37 sold.

HighMark Wealth Management first reported a position in ADAP in Q2 2023 and held it in 10 quarters. The position peaked at $1.17K in Q2 2023. 10 funds tracked by Wall St. Rank hold ADAP as of Q4 2025.

HighMark Wealth Management reported no remaining Adaptimmune Therapeutics position as of Q4 2025 after selling out during the quarter.
HighMark Wealth Management sold 287 Adaptimmune Therapeutics shares in Q4 2025, an estimated $37.
HighMark Wealth Management first reported a position in Adaptimmune Therapeutics in Q2 2023 and held it in 10 quarters.
HighMark Wealth Management's Adaptimmune Therapeutics position peaked at $1.17K in Q2 2023.
10 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2025.

Based on HighMark Wealth Management's 13F filing for Q4 2025, filed 5 Feb 2026.